DCM
Pre-clinical- Indications
- Sleep disorders, Physical activity monitoring
Company intelligence / Profile preview
PneumoWave has developed a chest-worn biosensor with an integrated digital health platform to monitor patients at risk of life-threatening respiratory events. The company’s technology has received FDA Class II clearance for its Data Collection Mobile system. Clinical trials are ongoing in collaboration with leading academic centers to validate the effectiveness of the system in opioid overdose prevention and management of chronic lung diseases.
The company’s ALERT product provides real-time alerts for opioid-induced respiratory depression, while DCM monitors physical movement during sleep/activity. Early results support utility in both clinical research settings and potential outpatient/home use.
No published pivotal trial outcomes yet; clinical validation ongoing as of mid–2025.1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PneumoWave.